ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.515,66
-1,13%
S&P 500
5.356,42
0,06%
US Dollar vs BRL
5,2906
0,61%
Bitcoin
69.570,05
-1,69%
Brent Oil
79,595
-0,36%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. 4D Molecular Therapeutics Inc (FDMT)

  7. 4D Molecular Therapeutics Inc (FDMT) Notícias

FDMT

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:FDMT
DataHoraFonteTítuloCódigoCompanhia
06/06/202408:30GlobeNewswire Inc.4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
04/06/202409:00GlobeNewswire Inc.4DMT Announces Presentations at Clinical Trials at the Summit 2024 MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
03/06/202409:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
30/05/202409:00GlobeNewswire Inc.4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202417:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
23/05/202420:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
09/05/202417:05GlobeNewswire Inc.4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
07/05/202409:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
01/05/202409:00GlobeNewswire Inc.4DMT Announces Presentations at ARVO 2024 Annual MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
28/03/202409:00GlobeNewswire Inc.4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202419:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202418:05GlobeNewswire Inc.4DMT Reports Full Year 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
14/02/202422:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
12/02/202410:00GlobeNewswire Inc.4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024NASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202418:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202418:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FDMT4D Molecular Therapeutics Inc
07/02/202421:42Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
07/02/202401:27GlobeNewswire Inc.4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:FDMT4D Molecular Therapeutics Inc
05/02/202418:35Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:FDMT4D Molecular Therapeutics Inc
05/02/202418:05GlobeNewswire Inc.4D Molecular Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:FDMT4D Molecular Therapeutics Inc
03/02/202419:00GlobeNewswire Inc.4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMDNASDAQ:FDMT4D Molecular Therapeutics Inc
29/01/202410:00GlobeNewswire Inc.4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment BurdenNASDAQ:FDMT4D Molecular Therapeutics Inc
23/01/202410:00GlobeNewswire Inc.4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung DiseaseNASDAQ:FDMT4D Molecular Therapeutics Inc
04/01/202410:00GlobeNewswire Inc.4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational UpdatesNASDAQ:FDMT4D Molecular Therapeutics Inc
03/01/202410:01GlobeNewswire Inc.4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS DiseasesNASDAQ:FDMT4D Molecular Therapeutics Inc
21/12/202314:31Dow Jones News4D Molecular Shares Rise on FDA Designation for Wet AMD DrugNASDAQ:FDMT4D Molecular Therapeutics Inc
21/12/202310:00GlobeNewswire Inc.4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMDNASDAQ:FDMT4D Molecular Therapeutics Inc
04/12/202310:00GlobeNewswire Inc.4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
09/11/202318:19GlobeNewswire Inc.4DMT Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
01/11/202317:00GlobeNewswire Inc.4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFCNASDAQ:FDMT4D Molecular Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:FDMT

Seu Histórico Recente

LSE
ZA81
Severn T.u 34
LSE
AG70
Ebrd 43
KUCN
BONDLYETH
Bondly Token
BIT
UC4Y3K
Unicredit Bank
BIT
UC346M
Unicredit Bank
ASX
MQGSOG
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados